Extracellular vesicles from IFN-γ-primed mesenchymal stem cells repress atopic dermatitis in mice

Journal of Nanobiotechnology, Год журнала: 2022, Номер 20(1)

Опубликована: Дек. 10, 2022

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by immune dysregulation, pruritus, and abnormal epidermal barrier function. Compared with conventional mesenchymal stem cell (MSC), induced pluripotent (iPSC)-derived (iMSC) recognized as unique source for producing extracellular vesicles (EVs) because it can be obtained in scalable manner an enhanced homogeneity. Stimulation of iMSCs cytokines improve the immune-regulatory, anti-inflammatory, tissue-repairing potential iMSC-derived EVs.Proteome analysis showed that IFN-γ-iMSC-EVs are enriched protein sets involved regulating interferon responses pathways. In AD mice, expression interleukin receptors Th2 (IL-4Rα/13Rα1/31Rα) activation their corresponding intracellular signaling molecules was reduced. decreased itching, which supported reduced infiltration mast cells mouse skin; IgE receptor thymic stromal lymphopoietin NF-kB activation; recovered impaired barrier, evidenced upregulation key genes differentiation lipid synthesis.IFN-γ-iMSC-EVs inhibit Th2-induced responses, suppress inflammation, facilitate restoration, contributing to improvement.

Язык: Английский

---

Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis

Heliyon, Год журнала: 2023, Номер 9(11), С. e22014 - e22014

Опубликована: Ноя. 1, 2023

In recent years, biologics targeting key cytokines and Janus kinase (JAK) inhibitors have demonstrated favorable efficacy safety outcomes for atopic dermatitis (AD) therapy. To evaluate the short-term of AD therapy involving biologics, JAK inhibitors, their combination with topical corticosteroids (TCS) patients AD, we conducted this systematic review meta-analysis. Using eligible randomized clinical trials (RCTs) 12 or 16 weeks treatment systemic medications 4 AD.PubMed, Web Science, ScienceDirect, Cochrane Library were searched from inception up to October 25, 2023. English-language included. Titles, abstracts, articles screened in duplicate. Of 7261 citations, 37 studies The data analyzed using Review Manager 5.4 measured by Eczema Area Severity Index (EASI), Investigator Global Assessment (IGA), pruritus Numerical Rating Scale (NRS), as well instances adverse events (AE), serious AE (SAE), which presented risk ratio (RR) a 95 % confidence interval (CI). biological therapies was percentage who achieved EASI 75, 90, IGA 0/1 NRS4, while treatments evaluated terms number had ≥1 at least one SAE.A total 43 cohorts that examined 9 placebo involved 18172 participants Compared placebo, all associated higher response rate outcomes, administration dupilumab 200 mg subcutaneously every 2 superior improvement 90 (RR 9.50, CI 2.31-39.03) IGA0/1 17.00, 2.33-123.78), upadacitinib 30 once daily 75 5.14, 4.20-6.31) Pruritus NRS4 5.73, 4.44-7.39), external use ruxolitinib 1.5 twice orally 4.14, 3.06-5.61) 4.08, 2.86-5.81), most doses led better profile. Most baricitinib, dupilumab, tralokinumab, TCS good compared control groups (placebo + TCS). However, receiving baricitinib dosage 1.23, 1.02-1.49) 1.39, 1.22-1.58) TCS, exhibited incidence more SAE those taking TCS.Our research has revealed are effective safe mild moderate severe respectively. Additionally, demonstrates greater background AD. We suggest could be potential alternative when used medications, novel approach treat Insufficient different sources caused partial interventions only mentioned few low event rates analyses may lead results being biased. Further directly comparing existing needed will included forthcoming updates review. Our findings form useful foundation developing new generation guidelines

Язык: Английский

---

Association between body mass index and atopic dermatitis among adolescents: Findings from a national cross-sectional study in Korea

PLoS ONE, Год журнала: 2024, Номер 19(7), С. e0307140 - e0307140

Опубликована: Июль 19, 2024

Background The association between atopic dermatitis and childhood overweight obesity has been studied extensively, but the results are inconclusive; most studies have focused on body mass index as a measure of obesity, with few investigating relationship underweight. Therefore, this study aimed to investigate levels in Korean adolescents. Methods 3-year (2019–2021) Korea Youth Risk Behavior Web-based Survey were used. Body was used recent diagnosis within past year criterion for dermatitis. Multiple logistic regression analyses performed explore associations. odds ratios (ORs) 95% confidence intervals (CIs) calculated. Results A total 144,183 adolescents aged 12–18 years included (74,704 males 69,479 females). Over year, 5.4% 7.3% females diagnosed population. Adolescents normal weight (males [OR: 1.19, CI: 1.02–1.38]; 1.26, 1.10–1.43]) 1.37, 1.16–1.61]; 1.19–1.58]) more likely develop than Conclusion Increased degree may contribute development normal-weight obese had higher likelihood developing compared underweight

Язык: Английский

---

Dermatologic Disease-Directed Targeted Therapy (D3T2): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions—Precision Dermatology

Dermatology and Therapy, Год журнала: 2022, Номер unknown

Опубликована: Сен. 19, 2022

Precision dermatology uses individualized dermatologic disease-directed targeted therapy (D

Язык: Английский

---

CS12192, a novel JAK3/JAK1/TBK1 inhibitor, attenuates autoimmune dermatoses in murine models

Immunopharmacology and Immunotoxicology, Год журнала: 2024, Номер 46(4), С. 529 - 537

Опубликована: Июнь 26, 2024

Autoimmune dermatosis (AID) occurs when the body's immune system attacks skin or tissue, leading to various types of disorders injuries. Recent studies show that Janus kinases (JAKs) play critical roles in autoimmune diseases including AID by regulating multiple cytokine signaling pathways. CS12192, a novel JAK3/JAK1/TBK1 inhibitor, has been reported exert ameliorative effects rheumatoid arthritis. However, efficacy CS12192 on is undetermined. This study aims investigate therapeutic psoriasis (PSO), systemic lupus erythematosus (SLE) and atopic dermatitis (AD) mouse models.

Язык: Английский

---